Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis.

Literature DB >> 29265333

Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis.

Ayalew Tefferi¹, Sahrish Shah¹, Mythri Mudireddy¹, Terra L Lasho¹, Daniela Barraco¹, Curtis A Hanson², Rhett P Ketterling³, Michelle A Elliott¹, Mrinal S Patnaik¹, Animesh Pardanani¹, Naseema Gangat¹.

Abstract

Entities: Disease

Keywords: monocyte; myeloproliferative; prognosis; prognostic; survival

Mesh：

Year: 2017 PMID： 29265333 DOI： 10.1111/bjh.15061

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Myelofibrosis osteoclasts are clonal and functionally impaired.

Authors: Ivo Veletic; Taghi Manshouri; Asha S Multani; C Cameron Yin; Lei Chen; Srdan Verstovsek; Zeev Estrov
Journal: Blood Date: 2019-02-11 Impact factor: 22.113

2. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Authors: Mrinal M Patnaik; Prateek A Pophali; Terra L Lasho; Christy M Finke; Pedro Horna; Rhett P Ketterling; Naseema Gangat; Abhishek A Mangaonkar; Animesh Pardanani; Ayalew Tefferi
Journal: Haematologica Date: 2019-01-03 Impact factor: 9.941

Review 3. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Authors: Andrew T Kuykendall; Eric Padron
Journal: Curr Hematol Malig Rep Date: 2019-12 Impact factor: 3.952

4. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Authors: Julia T Geyer; Elizabeth Margolskee; Spencer A Krichevsky; Daniele Cattaneo; Leonardo Boiocchi; Paola Ronchi; Francesca Lunghi; Joseph M Scandura; Maurilio Ponzoni; Robert P Hasserjian; Umberto Gianelli; Alessandra Iurlo; Attilio Orazi
Journal: Haematologica Date: 2019-09-19 Impact factor: 9.941

Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis.

1. Myelofibrosis osteoclasts are clonal and functionally impaired.

2. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Review 3. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

4. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

5. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.

Review 6. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

7. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Review 8. Accelerated Phase of Myeloproliferative Neoplasms.

9. How I diagnose and treat chronic myelomonocytic leukemia.

Review 10. Myelofibrosis Treatment Algorithm 2018.